TRVI
Trevi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.95
−1.71%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$15.39
From 52W high−23.33%
Volume2.11M
Market cap$2.13B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$15.39
From 52W high
−23.33%
Volume
2.11M
Market cap
$2.13B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−35.5x
P/E (TTM)
—
RSI (14)
28.3
MomentumView details →
1D Return
−1.71%
YTD Return
+19.17%
SummaryUpdated Jun 1, 2026
Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in New Haven, Connecticut. The company went public in May 2019 and focuses exclusively on developing <b>Haduvio</b>, an oral extended-release formulation of nalbuphine, to treat serious neurologically mediated conditions. Trevi operates under a licensing agreement with Endo Pharmaceuticals Inc. for the development and commercialization of nalbuphine hydrochloride-based products. The company is currently advancing multiple Phase 2 clinical trials targeting chronic cough conditions, representing a significant unmet medical need in respiratory medicine.
Similar companies
Latest newsMore news →
Trevi Therapeutics announced that Professor Marlies Wijsenbeek will present quality-of-life outcomes from the Phase 2b CORAL trial of nalbuphine ER at the ERS Congress 2026.25d agoTrevi Therapeutics began two clinical trials in Q2 2026 and plans to launch a third study in Q3 2026 for nalbuphine ER (Haduvio) in chronic-cough indications.44d agoMichael Heffernan was elected as a Class I director of Trevi Therapeutics, Inc., effective June 3, 2026.109d ago